Table 1.

Patient characteristics (n=65).

	N	%		N	%
Age			BRCA mutation
≤40	6	9.2	Positive	8	12.3
41-55	24	36.9	Negative	16	24.6
>55	35	53.9	Unknown	41	63.1
WHO performance status			Previous (neo)adjuvant chemotherapy
0	16	24.6	Yes	45	69.2
1	46	70.8	None	20	30.8
2	3	4.6
			Previous adjuvant endocrine therapy
Menopausal status			Yes	30	46.2
Premenopausal	10	15.4	None	35	53.8
Perimenopausal	9	13.9
Postmenopausal	45	69.2	Number of previous palliative chemotherapy agents
Unknown	1	1.5	0	5	7.7
			1	10	15.4
BR grade			2	18	27.7
1	0	0.0	3	17	26.2
2	16	24.6	4	10	15.4
3	27	41.5	5	3	4.6
Unknown	22	33.9	6	2	3.1
ER status			Number of previous palliative endocrine agents
Positive	47	72.3	0	27	41.5
Negative	18	27.7	1	11	16.9
			2	14	21.5
PR status			3	5	7.7
Positive	33	50.8	4	5	7.7
Negative	32	49.2	5	2	3.1
			6	1	1.5
HER2 status
Positive	2	3.1	PARP-inhibitor received previously
Negative	62	95.4	Yes	5	7.7
Unknown	1	1.5	None	60	92.3
Subtype
ER+/HER2-	44	67.7
ER+/HER2+	2	3.1
Triple negative	18	27.7
Unknown	1	1.5

Patient characteristics for all 65 patients. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.